Inactive

The Food and Drug Administration (FDA), the Office of Acquisitions and Grants Services (OAGS) intends to inform the public that the FDA anticipates issuing an award to purchase a PromethION 24 compact... The Food and Drug Administration (FDA), the Office of Acquisitions and Grants Services (OAGS) intends to inform the public that the FDA anticipates issuing an award to purchase a PromethION 24 compact benchtop system designed to run and analyze up to 24 PromethION Flow Cells (PR02) —delivering yields of up to 4,800 Gbases. The Period of Performance includes a one-year Base Period and three (1) year option years.